Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies

Fig. 1

Timeline to first and second dose reduction by treatment cycle. Bars represent the percentage of patients who required dose reduction in each cycle. First dose reduction was from 125 to 100 mg. Second dose reduction was from 100 to 75 mg. C, cycle occurring after the dose reduction

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us